Publications by authors named "Noel Barrett"

Claim this Profile
D
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Didier Scherrer, Noel Barrett, Luc Teyton, Tillman Pearce, Josianne Nitcheu

Mol Cancer Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study.
Sofie Rutsaert, Jean-Marc Steens, Paul Gineste, Basiel Cole, Sam Kint, P Noel Barrett

J Virus Erad· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
P Noel Barrett, Sara J Terpening, Doris Snow, Ronald R Cobb, Otfried Kistner

Expert Rev Vaccines· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
Jean-Marc Steens, Didier Scherrer, Paul Gineste, P Noel Barrett, Supparatpino Khuanchai

Antimicrob Agents Chemother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.
Didier Scherrer, Regine Rouzier, P Noel Barrett, Jean-Marc Steens, Paul Gineste

J Antimicrob Chemother· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.
Didier Scherrer, Regine Rouzier, Marine Cardona, P Noel Barrett, Jean-Marc Steens

Antimicrob Agents Chemother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus Vaccines.
Yvonne Beck, Richard Fritz, Klaus Orlinger, Stefan Kiermayr, Reinhard Ilk, P Noel Barrett

J Virol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.
Walter Wodal, Michael G Schwendinger, Helga Savidis-Dacho, Brian A Crowe, Christine Hohenadl, P Noel Barrett

PLoS One· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.
Nina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, Wolfgang Draxler, Maria O'Rourke, P Noel Barrett

Clin Vaccine Immunol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.
Gerald Aichinger, Barbara Grohmann-Izay, Maikel V W van der Velden, Sandor Fritsch, Manuela Koska, P Noel Barrett

Clin Vaccine Immunol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
Nina Wressnigg, P Noel Barrett, Eva-Maria Pöllabauer, Maria O'Rourke, Daniel Portsmouth

Clin Vaccine Immunol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.
Annett Hessel, Helga Savidis-Dacho, Sogue Coulibaly, Daniel Portsmouth, Thomas R Kreil, P Noel Barrett

PLoS One· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients.
Richard Fritz, Nicole Hetzelt, Reinhard Ilk, Christine Hohenadl, Maikel V W van der Velden, P Noel Barrett

Open Forum Infect Dis· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
Michael G Schwendinger, Maria O'Rourke, Andreas Traweger, Helga Savidis-Dacho, Andreas Pilz, P Noel Barrett

PLoS One· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
Maikel V W van der Velden, Alexander Geisberger, Thomas Dvorak, Daniel Portsmouth, Richard Fritz, P Noel Barrett

Clin Vaccine Immunol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice.
Christine Hohenadl, Walter Wodal, Astrid Kerschbaum, Richard Fritz, M Keith Howard, P Noel Barrett

Virol J· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.
Maikel V W van der Velden, Richard Fritz, Eva Maria Pöllabauer, Daniel Portsmouth, M Keith Howard, P Noel Barrett

J Infect Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lyme disease vaccination: safety first - authors' reply.
P Noel Barrett, Brian A Crowe, Nina Wressnigg, Daniel Portsmouth, Gerald Aichinger

Lancet Infect Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative detection of Borrelia burgdorferi sensu lato in erythema migrans skin lesions using internally controlled duplex real time PCR.
Maria O'Rourke, Andreas Traweger, Lara Lusa, Dasa Stupica, Vera Maraspin, P Noel Barrett

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies.
P Noel Barrett, Daniel Portsmouth

Expert Rev Vaccines· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Nina Wressnigg, Eva-Maria Pöllabauer, Gerald Aichinger, Daniel Portsmouth, Alexandra Löw-Baselli, P Noel Barrett

Lancet Infect Dis· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.
Larry R Smith, Walter Wodal, Brian A Crowe, Astrid Kerschbaum, Peter Bruehl, P Noel Barrett

Hum Vaccin Immunother· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.
P Noel Barrett, Daniel Portsmouth, Hartmut J Ehrlich

Expert Rev Vaccines· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The need for a new vaccine against lyme borreliosis.
P Noel Barrett, Daniel Portsmouth

Expert Rev Vaccines· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
Maikel V W van der Velden, Gerald Aichinger, Eva Maria Pöllabauer, Alexandra Löw-Baselli, Sandor Fritsch, P Noel Barrett

Vaccine· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis